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SDH5, a Gene Required for Flavination
of Succinate Dehydrogenase,
Is Mutated in Paraganglioma
Huai-Xiang Hao,1 Oleh Khalimonchuk,1,2 Margit Schraders,5,6 Noah Dephoure,7 Jean-Pierre Bayley,8
Henricus Kunst,5 Peter Devilee,8,9 Cor W. R. J. Cremers,5 Joshua D. Schiffman,3 Brandon G. Bentz,4
Steven P. Gygi,7 Dennis R. Winge,1,2 Hannie Kremer,5,6 Jared Rutter1*
Mammalian mitochondria contain about 1100 proteins, nearly 300 of which are uncharacterized. Given
the well-established role of mitochondrial defects in human disease, functional characterization of these
proteins may shed new light on disease mechanisms. Starting with yeast as a model system, we
investigated an uncharacterized but highly conserved mitochondrial protein (named here Sdh5). Both
yeast and human Sdh5 interact with the catalytic subunit of the succinate dehydrogenase (SDH) complex,
a component of both the electron transport chain and the tricarboxylic acid cycle. Sdh5 is required for
SDH-dependent respiration and for Sdh1 flavination (incorporation of the flavin adenine dinucleotide
cofactor). Germline loss-of-function mutations in the human SDH5 gene, located on chromosome
11q13.1, segregate with disease in a family with hereditary paraganglioma, a neuroendocrine tumor
previously linked to mutations in genes encoding SDH subunits. Thus, a mitochondrial proteomics
analysis in yeast has led to the discovery of a human tumor susceptibility gene.
Mitochondrial defects have been impli-cated in a variety of human disorders,including cancer (1, 2). Nearly one-
third of the mammalian mitochondrial proteome
is currently uncharacterized. Many of these un-
characterized proteins are evolutionarily conserved,
a strong indication that they perform fundamentally
important cellular functions (3). We initiated a
project to determine the function of one of these
proteins, named here Sdh5, using yeast as the
primary model system. The Sdh5 protein family
is highly conserved in eukaryotes and in some
prokaryotic species, including Rickettsia, which
is related to the bacterium that became the an-
cestral mitochondrion (fig. S1) (4, 5).
The mitochondrial localization of yeast Sdh5
(originally named EMI5/YOL071W) was suggested
by proteomics studies (6), and we confirmed this
by fluorescence microscopy of a strain expressing
Sdh5–green fluorescent protein and subcellular frac-
tionation of a strain expressing Sdh5-GFP (green
fluorescent protein) (figs. S2 and S3). Both forms of
tagged Sdh5 were expressed from the native SDH5
promoter and were fully functional. We further
showed that Sdh5 resides in the mitochondrial matrix
(Fig. 1A) and is predominantly soluble (Fig. 1B).
Respiratory-deficient mutants of S. cerevisiae
are viable on fermentable carbon sources such as
glucose, but are inviable on nonfermentable carbon
sources such as glycerol.We found that a yeast strain
with a deletion of SDH5 (sdh5D) grew normally on
glucose medium but failed to grow on glycerol me-
dium, a phenotype that was rescued by an SDH5-
expressing plasmid (Fig. 1C). The sdh5D strain also
showed impaired oxygen consumption, similar to
the respiratory-deficient sdh1D strain (7) (Fig. 1D),
as well as the respiration-related phenotypes of
H2O2 hypersensitivity and decreased chronological
life-span (figs. S4 and S5). The sdh5D respiratory
deficiency was not due to defective mitochondrial
DNA (mtDNA), because the sdh5D strain com-
plemented the glycerol growth defect of a rho0
(mtDNA-deficient) strain in mating tests (fig. S6).
Thus, the sdh5D strain is respiratory-deficient, de-
spite having a functional mitochondrial genome.
Silver staining of the final eluates from tan-
dem affinity purification of Sdh5-His6/HA revealed
two proteins specific for tagged Sdh5 as compared
to the wild type, including Sdh5 itself at ~22 kD
(Fig. 1E). The second migrated at ~70 kD and
was identified by mass spectrometry as Sdh1, the
catalytic subunit of the succinate dehydrogenase
(SDH) complex. The presence of both Sdh5 and
Sdh1 in the final eluate was confirmed by im-
munoblot (Fig. 1E). The SDH complex is a com-
ponent of both the tricarboxylic acid (TCA) cycle
and the electron transport chain (ETC). In the
latter, the SDH complex is known as complex II.
It is a highly conserved heterotetramer, with Sdh1
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Fig. 1. Sdh5 is required for
respiration and interacts with
Sdh1. (A) Mitochondria, mito-
plasts generated by hypotonic
swelling, and 1% Triton X-
100–solubilized mitochondria
from a strain expressing Sdh5-HA
were treated with (+) or without
(–) proteinase K and analyzed by
immunoblotting with an untreated
mitochondria control (UT). Mge1,
Tim10, and Fzo1 are matrix,
intermembrane space, and outer
membrane proteins, respectively.
(B) Soluble and membrane frac-
tions of purified mitochondria (4)
as in (A) were immunoblotted.
Aco1, soluble matrix protein;
Sdh1, membrane-associated ma-
trix protein. (C) Serial dilutions of
WT and sdh5D strains containing
empty vector (EV) or a plasmid
expressing Sdh5-HA were spotted
on glucose or glycerol medium
and grown at 30°C for 2 or 3 days,
respectively. (D) Oxygen consump-
tion in WT, sdh5D, and sdh1D
strains grown to mid-log phase
in raffinose media (TSD, n = 3
biological replicates). Similar results
were obtained in glucose medium.
(E) Tandem purification eluates (4)
from a WT strain and a strain
expressing Sdh5-His6/HA were resolved with SDS-PAGE and visualized by silver staining (top panel) or
immunoblot with antibodies to Sdh1 and HA (lower panels). (F) Immunoblot of purified mitochondria from
WT, sdh1D, or sdh2D strains expressing Sdh5-HA. Porin, mitochondrial loading control.
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and Sdh2 as catalytic subunits anchored to the
mitochondrial inner membrane by Sdh3 and Sdh4
(fig. S12) (8). Both sdh1D and sdh5D mutants
were respiratory-deficient and failed to grow on
glycerol medium, but grew weakly with ethanol
as the carbon source (Fig. 1D and fig. S7) and ex-
hibited acetate hyperexcretion, a phenotype shared
by only four other TCA cycle mutants (9). The
importance of the Sdh1-Sdh5 interaction was con-
firmed by the observation that Sdh5 (like Sdh2) is
completely degraded in the sdh1D strain (Fig. 1F).
In contrast, loss of SDH2 led to an increase in the
Sdh5 protein level (Fig. 1F), presumably due to
enhanced Sdh1/Sdh5 complex formation in the
absence of Sdh2, the major Sdh1 partner.
The Sdh1-Sdh5 interaction is likely to be
functionally important because the sdh5Dmutant
lacks SDH activity (Fig. 2A), as previously
observed for the sdh1D mutant (10). The activity
of malate dehydrogenase, another TCA cycle en-
zyme, was not affected by SDH5 deletion (Fig.
2A). Because SDH is complex II in the ETC, we
performed in-gel activity staining of ETC complexes
after separation by blue native–polyacrylamide
gel electrophoresis (BN-PAGE). As shown in Fig.
2B, complex II/SDH activity was absent in the
sdh5Dmutant, whereas the activities of complexes
IV and V were normal. We then examined ETC
complex assembly and stability byCoomassie blue
staining after BN-PAGE and found that complex
II/SDHwas specifically absent in sdh5Dmitochon-
dria (Fig. 2C). The loss of complex II/SDH in the
sdh5D mutant was confirmed by anti-Myc immu-
noblot after BN-PAGE of wild-type (WT) and
sdh5D strains expressing Sdh3-Myc (Fig. 2D).
Sdh5 is not a stable component of complex II/SDH
because it migrates in a ~90-kD SDS-sensitive com-
plex during BN-PAGE (Fig. 2E), which is distinct
from complex II (~200 kD). This ~90-kD complex
is likely to be the Sdh5-Sdh1 (70-kD) heterodimer.
The levels of all four SDH subunits were sig-
nificantly decreased in the sdh5D mutant, probably
because of degradation in the absence of a stable
SDH complex (Fig. 2F, lane 1 versus lane 2). The
residual Sdh1 level was higher than that of the
other subunits, but much of it was in the soluble
fraction, unassociated with the SDH complex (Fig.
2F). These data suggest that the SDH complex as-
sembles in the absence of Sdh5, but the complex is
nonfunctional and Sdh1 is not stably bound. As a
result, the unstable complex is more susceptible to
degradation and is disrupted by detergent extrac-
tion during the BN-PAGE procedure (the fraction-
ation shown in Fig. 2F was detergent-free).
Multiple cofactors are required for activity of the
SDHcomplex, including the flavin adenine dinucle-
otide (FAD) in Sdh1 (11). In other ETC complexes,
cofactors are important for complex assembly and
stability in addition to enzymatic activity (12). The
strongly fluorescent FAD is covalently attached to
Sdh1 and can be detected by in-gel fluorometry after
SDS-PAGE (13). Deletion of SDH5 caused a com-
plete loss of FAD cofactor attachment (flavination)
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Fig. 2. Sdh5 is required for SDH activity and stability. (A) SDH andmalate dehydrogenase
activity (4) from WT and sdh5D mitochondria, normalized to total protein (TSD, n = 3
biological replicates). (B) In-gel activity assay of ETC complexes after BN-PAGE of mito-
chondrial membranes from WT and sdh5D strains. V2, complex V dimer. (C) Coomassie-
stained BN-PAGE ofmitochondrial membranes fromWT and sdh5D strains. (D) Immunoblot
of BN-PAGE–separated complex II/SDH using an antibody to Myc to show Myc-tagged Sdh3
in WT and sdh5D mitochondria. (E) Immunoblot of BN-PAGE–separated WT and Sdh5-TAP
mitochondria using an antibody to TAP, without and with 1% SDS pretreatment. Porin is
an ~440-kD control. (F) Immunoblot of mitochondria from WT and sdh5D strains in
which Sdh3 or Sdh4 was Myc-tagged, separated into soluble (sol) and membrane (mem)
fractions (4), or unfractionated (total). Aco1, soluble matrix protein. The indicated per-
centage is the amount remaining in sdh5D mitochondria relative to WT mitochondria.
Fig. 3. Sdh5 is neces-
sary and sufficient for
Sdh1 flavination. (A)
WT, sdh5D, and sdh1D
mitochondria were re-
solved by SDS-PAGE
and imaged (4) for co-
valent FAD (top panel)
or immunoblotted (low-
er panels). (B) Fluores-
cence gel image (top
panel) and immuno-
blot (lower panels) as in
(A), with whole-cell ex-
tract from WT or flx1D
sdh5D strains contain-
ing EV, CEN plasmid
SDH5 (flx1D: ~1 copy
per cell), or 2m plasmid
SDH5 (O/E: ~10 copies
per cell). The bar graph
shows normalized FAD
fluorescence (TSD, n = 3 biological replicates) (bottom panel). (C) His-tagged yeast Sdh1 was expressed alone or
with Sdh5 or Sdh2 in E. coli, purified, and analyzed for FAD fluorescence as in (A) and by Coomassie blue staining.
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of Sdh1, although Sdh1 was still present (Fig. 3A).
The flavination of two other mitochondrial flavo-
proteins, visualized in the same gel, was unaffected
by either SDH5 or SDH1 deletion (Fig. 3A).
Sdh5 overexpression in WT cells did not in-
crease Sdh1 flavination (Fig. 3B, lane 1 versus lane
2), possibly due to flavination that was already
stoichiometric. A significant effect of Sdh5 over-
expression might require a state of reduced Sdh1
flavination as was observed in a strain with de-
creasedmitochondrial FAD caused by deletion of
the mitochondrial FAD transporter Flx1 (13, 14).
The flx1D mutant displayed almost no Sdh1
flavination, but Sdh5 overexpression restored
flavination to about 50% of WT levels (Fig. 3B,
lanes 4 and 5). As shown in Fig. 3C, FAD in-
corporationwas almost undetectable inEscherichia
coli–expressed Sdh1 but was increased dramat-
ically when Sdh5, but not Sdh2, was coexpressed.
These data demonstrate that Sdh5 is both nec-
essary and sufficient for Sdh1 flavination.
The amino acid sequence of yeast Sdh5 is 44%
identical (from residues 33 to 158 of 163) to its
human ortholog C11orf79, which we rename here
hSDH5 (fig. S1).We hypothesized that hSDH5 is
required for flavination of SDHA (human Sdh1)
and thus for SDH activity. Previous genetic studies
have shown that mutations causing loss of SDH
activity are responsible for hereditary forms of a rare
neuroendocrine tumor called paraganglioma (PGL).
Of the four familial PGLsyndromes (PGL1 toPGL4),
PGL1, PGL3, and PGL4have been associatedwith
mutations in SDHD, SDHC, and SDHB, respec-
tively (15). The gene for PGL2 (Online Mendelian
Inheritance inMan number%601650) has not been
identified, but it maps to chromosome 11q13.1, the
genomic locus of the hSDH5 gene (16).
We sequenced hSDH5 in three affected indi-
viduals from different branches of the previously
described Dutch PGL2 lineage (17). In all three in-
dividuals, we found a single nucleotide c.232G>A
change in exon 2 (fig. S8), which causes aGly78→
Arg78 (G78R) mutation in the most conserved
region of the protein (fig. S1). None of 400 un-
affected control individuals carried the c.232G>A
DB
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unaffected persons; +, heterozygousmutation;NT, not tested. Diamondswith the number 4 represent
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mutation.Within the affected lineage, themutation
was found to cosegregatewith the disease haplotype
in all 45 individuals who inherited this haplotype,
and was not detected in 44 unaffected members
without this haplotype. Thirty-three individuals with
the mutation have developed the disease, but not
seven individuals (2009 median age = 74 years)
who inherited the mutation from their mother (Fig.
4A). This suggests an SDHD-like parent-of-origin-
specific inheritance pattern. Only five individuals
(2009 median age = 42 years) with a paternal mu-
tation have not developed overt PGL. Because
penetrance of the disease increases with age (17),
these individualsmay develop tumors in the future,
or tumors may already be present but undetected.
SDHA flavination was decreased by ~95% in
tumors from three patients with PGL2 (hSDH5
G78R) in comparison with control tumors from
two sporadic PGL patients or with cultured human
embryonic kidney and hepatoma cells and mouse
skeletal muscle and liver tissue (Fig. 4B). Mito-
chondrial localization of hSDH5 was not com-
promised by this mutation (fig. S9). As observed
in yeast, SDHA coimmunoprecipitated with WT
hSDH5-Myc. The G78R hSDH5mutation, how-
ever, dramatically impaired the interaction of
hSDH5 with SDHA and slightly decreased the
level of hSDH5 protein (Fig. 4C). We conclude
that the G78R mutation destabilizes hSDH5 and
impairs its interaction with SDHA.
When expressed in yeast from the yeast SDH5
promoter, WT hSDH5 complemented the sdh5D
glycerol growth defect, but the G78R mutant had
no effect (Fig. 4D). Overexpression of any of the
individual SDH subunits or the proposed SDH
chaperone TcM62 (18) failed to complement the
sdh5D mutant phenotype (fig. S10). Further, an ex-
tensive high-copy suppressor screen of the sdh5D
glycerol growth defect using a yeast genomic
library recovered many independent isolates of
SDH5 but failed to identify any other suppressing
genes. Therefore, the specific rescue of the sdh5D
glycerol growth defect by native-level expression
of hSDH5 is strong evidence of the conservation
of Sdh5 function from yeast to humans. Further-
more, expression of hSDH5 in an sdh5D mutant
strain increased the flavination of yeast Sdh1 to
77% of the WT level, but the G78R mutant had
no effect (Fig. 4E). The lack of activity of the
G78R hSDH5 mutant in yeast is likely due to
destabilization of the protein (Fig. 4E).
The mechanism of covalent FAD insertion into
proteins is controversial. Although other covalent
cofactors are inserted by specialized enzymes (19),
an autocatalytic mechanism has been proposed for
flavination (20). However, covalent FAD attach-
ment to Sdh1 was shown to require at least one
additional protein (21), whichwehypothesize to be
Sdh5. Whether Sdh5 participates in the chemistry
of FAD attachment (enzymatic function) or simply
maintains Sdh1 in a conformation that is susceptible
to autocatalytic FAD attachment (chaperone func-
tion) is a question that remains to be addressed.
The identification of hSDH5 as thePGL2 gene
has potential clinical implications. Approximately
70% of familial cases of head and neck PGL are
due to germline mutations in SDHB, SDHC, or
SDHD (22), and 10% of sporadic PGL cases are
associated with mutations in SDHB or SDHD
(23, 24). Mutations in SDHB, SDHC, and SDHD
have also been detected in gastrointestinal stromal
tumors (25), pheochromocytomas (24), renal cell
carcinoma (26), and other diseases (27). Conceiv-
ably, hSDH5 mutations may underlie disease de-
velopment in patients who have tested negative for
mutations in SDHB, SDHC, and SDHD.The inclu-
sion of hSDH5 will allow more comprehensive
genetic testing, which is suggested for the clinical
management of PGL, even for sporadic cases (28).
The same is also true of the SDHAF1 gene, which
encodes a protein involved in SDH assembly and
which was recently identified as a causative factor
in infantile leukoencephalopathy (29). In summary,
starting with a previously uncharacterized mito-
chondrial protein in yeast, we have shown through
biochemical and genetic analyses that the protein
plays a critical role in the biogenesis and function of
a respiratory complex and that its mutational in-
activation confers tumor susceptibility in humans.
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Eos Mediates Foxp3-Dependent Gene
Silencing in CD4+ Regulatory T Cells
Fan Pan,1 Hong Yu,1 Eric V. Dang,1 Joseph Barbi,1 Xiaoyu Pan,1 Joseph F. Grosso,1
Dinili Jinasena,1 Sudarshana M. Sharma,2 Erin M. McCadden,1 Derese Getnet,1
Charles G. Drake,1 Jun O. Liu,3 Michael C. Ostrowski,2 Drew M. Pardoll1*
CD4+ regulatory T cells (Tregs) maintain immunological self-tolerance and immune homeostasis by
suppressing aberrant or excessive immune responses. The core genetic program of Tregs and their ability
to suppress pathologic immune responses depends on the transcription factor Foxp3. Despite progress
in understanding mechanisms of Foxp3-dependent gene activation, the molecular mechanism of
Foxp3-dependent gene repression remains largely unknown. We identified Eos, a zinc-finger transcription
factor of the Ikaros family, as a critical mediator of Foxp3-dependent gene silencing in Tregs. Eos
interacts directly with Foxp3 and induces chromatin modifications that result in gene silencing in Tregs.
Silencing of Eos in Tregs abrogates their ability to suppress immune responses and endows them with
partial effector function, thus demonstrating the critical role that Eos plays in Treg programming.
Naturally occurring CD4
+CD25+ regula-
tory T cells (Tregs), which specifically
express the transcription factor Foxp3,
are essential for the suppression of pathological
immune responses to both self and foreign anti-
gens (1–3). Although it has been shown that
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